@article{e571cb4bc737418ab5741bdd4c2d00c9,
title = "Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
keywords = "Humans, Immunotherapy, Adoptive, Cost-Benefit Analysis, Antigens, CD19, Lymphoma, Large B-Cell, Diffuse/drug therapy",
author = "Choe, \{Jee H.\} and Hisham Abdel-Azim and Padula, \{William V.\} and Mohamed Abou-El-Enein",
note = "Publisher Copyright: {\textcopyright} 2022 American Medical Association. All rights reserved.",
year = "2022",
month = dec,
day = "15",
doi = "10.1001/jamanetworkopen.2022.45956",
language = "English",
volume = "5",
pages = "e2245956",
journal = "JAMA Network Open",
issn = "2574-3805",
number = "12",
}